Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 25 versus TESTOSTERONE UNDECANOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 25 versus TESTOSTERONE UNDECANOATE.
ANDROID 25 vs TESTOSTERONE UNDECANOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Testosterone undecanoate is a prodrug of testosterone, which binds to androgen receptors (ARs) in target tissues, leading to activation of androgen-responsive genes that promote male sexual development, maintenance of secondary sexual characteristics, and anabolic effects. It also exerts negative feedback on the hypothalamic-pituitary-gonadal axis, suppressing gonadotropin secretion.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
1000 mg intramuscularly every 10-14 weeks, followed by a second dose at 6 weeks; maintenance 1000 mg every 10-14 weeks.
None Documented
None Documented
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Terminal elimination half-life: 20.7 days (range 16.5–25.7 days) after intramuscular injection. This prolonged half-life is due to slow release from the oily depot in muscle. With oral administration, half-life is approximately 7–13 hours.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Renal (5-10% as glucuronide and sulfate conjugates, <1% as unchanged testosterone), Fecal (90% as metabolites via bile). No significant biliary excretion of active drug.
Category C
Category D/X
Androgen
Androgen